Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine composition for treating bone marrow hyperplasia and osteocarcinoma and application of medicine composition

A bone marrow proliferation and composition technology, which is applied in the direction of drug combination, boron compound active ingredients, bone diseases, etc., can solve the problems of unsatisfactory treatment effect and human side effects

Active Publication Date: 2016-06-22
浙江药苑生物科技有限公司
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, the drugs for the treatment of myelodysplasia are mainly concentrated in traditional Chinese medicine composition and T-2 toxin, but these methods will inevitably produce certain side effects on the human body, and the therapeutic effect is not very ideal

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition for treating bone marrow hyperplasia and osteocarcinoma and application of medicine composition
  • Medicine composition for treating bone marrow hyperplasia and osteocarcinoma and application of medicine composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] The acquisition of embodiment 1 polypeptide

[0015] Weigh 2g of the leaves of Echinacea dwarf, mash and prepare PBS aqueous solution with a substrate concentration of 5%, adjust the pH to 8.0, add trypsin 4000U / g leaves, enzymolysis temperature is 50°C, and after 90min of enzymolysis, the enzyme The solution was rapidly heated to 90°C and kept for 20 minutes for enzyme inactivation treatment. Then quickly cooled to room temperature, centrifuged at 3000r / min for 15min, and took the supernatant. According to the ratio of 100 grams: 100ml, trypsin hydrolyzate was added to the wet macroporous adsorption resin DA201-C, kept on a constant temperature shaker at 25°C for 180min, the rotating speed was 150r / min, eluted with 75% ethanol solution for 120min, and collected different eluent for the time period. The small molecular weight bands were recovered, and a total of 78 small peptide sequences were obtained. It has been verified that 29 small peptides have the function of...

Embodiment 2

[0016] The preparation of embodiment 2 pharmaceutical compositions

[0017] Take 0.01 part of GATA-1 polypeptide, 1 part of starch, an appropriate amount of cyclamate or / and sucrose as sweetener, and 0.1 part of benzoic acid, mix well, pass through a 50-mesh sieve, sterilize, and pack.

[0018] GATA-2-29 polypeptides are also prepared into corresponding compositions according to the preparation method of GATA-1 polypeptide.

Embodiment 3

[0019] The mixing of embodiment 3 pharmaceutical composition and other preparations

[0020] Mix the GATA-1 polypeptide and bortezomib according to the ratio of 1:0.75, and then take the weight of the mixed drug as the basic number, then add 1 part of starch, appropriate amount of cyclamate or / and sucrose as sweetener, benzoic acid 0.1 portion, mixed evenly, passed through a 50-mesh sieve, sterilized, and packaged.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a medicine composition in preparing medicine for treating osteocarcinoma and myeloproliferative disorder. The medicine composition includes GATA polypeptide, and can also be jointly administrated with bortezomib. The effective therapeutic dose of the medicine composition is 0.1-20 mg / Kg (body weight), and the medicine composition can be administrated in an oral mode or a mainline mode or a subcutaneous injection mode or an intramuscular injection mode in the administrating process. It is shown through experiments that polypeptide can inhibit growth of tumor cells, a good inhibiting effect on osteocarcinoma and myeloproliferative disorder is achieved, and wide application can be achieved.

Description

technical field [0001] The invention relates to the preparation and application of medicines for treating myeloid hyperplasia and bone cancer. Background technique [0002] The etiology of bone tumors is still unknown. In the past, it was believed that injuries, especially chronic minor injuries and chronic infections, could cause bone tumors. The onset age of bone tumors is 15-24 years old for males and 5-14 years old for females, which may be related to the time and duration of bone growth and endocrine development in different genders. Multiple myeloma is a malignant tumor with abnormal proliferation of plasma cells, a progressive neoplastic disease. Characterized by plasmacytoma of the bone marrow and hyperplasia of monoclonal immunoglobulins (IgG, IgA, IgD, or IgE) or Bence Jones proteins (free monoclonal kappa or gamma light chains), multiple myeloma is often accompanied by multiple myeloma. Bone damage, hypercalcemia, anemia, kidney damage, and increased susceptibil...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/10A61K36/899A61P7/00A61P35/00C07K7/08A61K31/69
CPCA61K31/69A61K36/899A61K38/05A61K38/10A61K2236/19A61K2236/55A61P7/00A61P19/08A61P35/00C07K7/08A61K2300/00
Inventor 曹帅
Owner 浙江药苑生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com